Stock Scorecard
Stock Summary for Abbvie Inc (ABBV) - $166.82 as of 4/25/2024 7:10:47 PM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ABBV
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ABBV
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ABBV
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for ABBV
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for ABBV
Financial Details for ABBV
Company Overview |
|
|---|---|
| Ticker | ABBV |
| Company Name | Abbvie Inc |
| Country | USA |
| Description | AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 4/26/2024 |
Stock Price History |
|
| Last Day Price | 166.82 |
| Last Day Price Updated | 4/25/2024 7:10:47 PM EST |
| Last Day Volume | 0 |
| Average Daily Volume | 6,007,967 |
| 52-Week High | 181.20 |
| 52-Week Low | 125.85 |
| Last Price to 52 Week Low | 32.55% |
Valuation Measures |
|
| Trailing PE | 61.69 |
| Industry PE | 101.20 |
| Sector PE | 61.73 |
| 5-Year Average PE | 8.64 |
| Free Cash Flow Ratio | 23.04 |
| Industry Free Cash Flow Ratio | 12.66 |
| Sector Free Cash Flow Ratio | 30.74 |
| Current Ratio Most Recent Quarter | 0.87 |
| Total Cash Per Share | 7.24 |
| Book Value Per Share Most Recent Quarter | 5.87 |
| Price to Book Ratio | 27.74 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 5.29 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
| Total Shares Outstanding | 1,770,650,000 |
| Market Capitalization | 295,379,833,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 4/12/2024 |
| Last Dividend Amount | 1.55 |
| Current Dividend Amount | 1.55 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 6.06 |
| Trailing Annual Dividend Yield | 3.61% |
| Forward Annual Dividend Rate | 6.57 |
| Forward Annual Dividend Yield | 3.92% |
| 5-Year Dividend Payments Count | 20 |
| 3-Year Average Dividend Yield | 3.72% |
| 5-Year Average Dividend Yield | 4.08% |
| 1-Year Dividend Growth Rate Percentage | 4.96% |
| 3-Year Dividend Growth Rate Percentage | 6.70% |
| 5-Year Dividend Growth Rate Percentage | 8.45% |
| All-Time Dividend Growth Rate Percentage | 13.98% |
| Dividend Payout Ratio | 223.62% |
Income Statement |
|
| Quarterly Earnings Growth YOY | -66.90% |
| Annual Earnings Growth | -58.91% |
| Reported EPS 12 Trailing Months | 2.72 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 11.11 |
| Net Income Twelve Trailing Months | 4,863,000,000 |
| Net Income Past Year | 4,863,000,000 |
| Net Income Prior Year | 11,836,000,000 |
| Quarterly Revenue Growth YOY | -5.40% |
| 5-Year Revenue Growth | 10.65% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 12,816,000,000 |
| Total Cash Past Year | 12,816,000,000 |
| Total Cash Prior Year | 9,229,000,000 |
| Net Cash Position Most Recent Quarter | -46,429,000,000 |
| Net Cash Position Past Year | -46,429,000,000 |
| Long Term Debt Past Year | 59,245,000,000 |
| Long Term Debt Prior Year | 63,128,000,000 |
| Total Debt Most Recent Quarter | 59,245,000,000 |
| Equity to Debt Ratio Past Year | 0.15 |
| Equity to Debt Ratio Most Recent Quarter | 0.15 |
| Total Stockholder Equity Past Year | 10,360,000,000 |
| Total Stockholder Equity Prior Year | 17,254,000,000 |
| Total Stockholder Equity Most Recent Quarter | 10,360,000,000 |
Options |
|
| Put/Call Ratio | 0.30 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -2.82 |
| MACD Signal | -2.37 |
| 20-Day Bollinger Lower Band | 149.30 |
| 20-Day Bollinger Middle Band | 167.28 |
| 20-Day Bollinger Upper Band | 185.26 |
| Beta | 0.56 |
| RSI | 44.41 |
| 50-Day SMA | 150.24 |
| 200-Day SMA | 124.50 |
System |
|
| Modified | 4/25/2024 4:19:21 PM EST |